Young Han, Chae
Bedia, Jacob S.
Yang, Wei-Lei
Hawley, Sarah J.
Bergan, Lindsay
Hopper, Marika
Celestino, Joseph
Guo, Jing
Gornet, Terrie G.
Soosaipillai, Antoninus
Yang, Hailing
Doskocil, Samantha D.
Lokshin, Anna E.
Handy, Beverly C.
Diamandis, Eleftherios P.
Moore, Richard G.
Lu, Karen H.
Lu, Zhen
Anderson, Karen S.
Drescher, Charles W.
Skates, Steven J. http://orcid.org/0000-0001-9249-4316
Bast, Robert C. Jr http://orcid.org/0000-0003-4621-8462
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (U01 CA200462, R01 CA247220, R01 CA247220, U01 CA117374, U01 CA152990)
Cancer Prevention and Research Institute of Texas (RP160145)
Article History
Received: 4 March 2023
Revised: 23 November 2023
Accepted: 14 December 2023
First Online: 9 January 2024
Competing interests
: RCB receives royalties from Fujirebio Diagnostics Inc. for the discovery of CA125. Massachusetts General Hospital has co-licensed software for ROCA to Abcodia, now owned by GenInCode, with MGH license revenue to MGH and research laboratories per MGH institutional policies.
: This study was approved by the Institutional Review Board (IRB) protocols at the University of Texas M.D. Anderson Cancer Center (MDACC: LAB04-0687), Fred Hutchinson Cancer Center (FHCC: 4563), University of Rochester (IRB exempt) and through the NROSS trial (NCT00539162). All informed consent was obtained by enrolled participants. This study was performed in accordance with the Declaration of Helsinki.